PhRMA sues Trump administration over Medicare price linking pilot program

The pharmaceutical trade group PhRMA has filed a lawsuit against the Trump administration, challenging a pilot program that would tie Medicare drug prices to the levels seen in peer countries. The suit argues that the approach could undermine pricing strategies for brand‑name medicines in the United States.

At the same time, smaller biotech companies are expressing frustration over recent tariff policies that they say increase costs and hinder global supply chains. Industry leaders note that the tariffs add financial pressure at a time when many firms are seeking to expand research and development activities.

Separately, the administration is considering a temporary allowance for the sale of certain peptides that were previously restricted. This potential policy shift could open new market opportunities for manufacturers that produce these specialized compounds.